Work Together to Drive Change
If your company or organization ​uses any combination of crystallographic data and pattern matching algorithms in order to conduct drug discovery then we would be happy to talk to you about licensing our technology.
​
If you use generative AI or have proprietary technology that utilizes our intellectual property then we would love to help you progress by providing you with patent coverage.
Crystallographic Data
Pattern Matching
Algorithms
DNA SEQ is the global pioneer in using algorithms and crystallographic data in targeted cancer therapy using patients’ genomic data in order to develop new drug binding sites of patients validated targets, new drugs for those sites, and have been awarded numerous patents to cover all applications involved in targeted cancer drug discovery.
Licensing
We license our technology to research organizations, biotech firms as well as pharmaceutical, diagnostic and many other companies who are looking to bring change to targeted therapies. We aim to partner with leading innovators in order to bring new discoveries to life.
We understand the complexity of creating novel approaches to novel drug development and the need for pattern matching and/or machine learning algorithms trained on crystallographic data to bring about change. Our team are global experts who were involved in the discovery of the kinase inhibitor field of targeted therapies. We don't interfere with your existing proprietary technologies.
We keep it simple.
Collaboration
There are areas that may provide for collaboration with DNA SEQ in our area of specialty. If you would like to discuss working with us on collaborative efforts, we know there are exceptional people and groups that we can create solutions with.
Why you should talk to us about licensing
DNA SEQ is uniquely positioned to identify appropriate therapeutic selections of targeted therapy drug regimens and understand which treated patients are at risk of developing cancer drug resistance.
​
DNA SEQ reduces risk for preclinical drug owners by predicting which small molecules will be clinically beneficial and will also have significant lower drug resistance potential prior to expensive clinical trials. Our licensing agreements are applicable to small and large molecule drug development.
​
Applications for our awarded patents includes:
​
We have patent coverage over the use of genetic data, crystallographic structure data, and algorithms (pattern matching and/or machine learning) used in any combination to generate new drugs of any kind in drug design from 2015 when our patents were awarded. This includes:
-
Algorithms to predict the functionality of a gene mutation, predict the specificity of a small molecule kinase inhibitor and to streamline drug development by the prediction of virtual molecules to inhibit kinases;
-
Prediction of activating and resistant gene mutations and their use in new drug development;
-
Prediction of drugs that allow analysis of one or more treatment options with a higher or lower likelihood of efficacy;
-
Identifying new therapeutic agents through the use of genomic and/or three-dimensional crystallographic analysis and the determination of a second drug based on the mutations for resistance by the first drug as well as searching crystal structure libraries to identify scaffolds for new drug candidates as the second drug;
-
Identifying the most optimal course of therapeutic treatment and subsequent treatments based on any human specimen type to determine resistance resulting from the first treatment;
-
Using a pattern matching algorithm and a crystal structure library to identify therapeutic agents to target the acting mutation or for which the patient is resistant in order to identify a therapeutic regiment or predicting resistance to a therapeutic regimen;
-
Using biologics and most all human genetic specimens used in predicting resistance for cancer patients;
-
Cross-linking agents, alkylating agents, DNA binding agents, monoclonal antibodies conjugated with anticancer drugs and numerous other approaches for preparing such drugs are covered;
-
Our patents are considered valid and enforceable as related to the use of algorithms and crystallographic data in targeted drug discovery.​​
Foundation of IP Licensing
Industry Papers on Generative AI
We are the go-to partner for companies that use Generative AI which is a pattern matching tools. Read about it here: